Seigo Nakamura
Overview
Explore the profile of Seigo Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
210
Citations
2420
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura S, Kojima Y, Takeuchi S
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996890
Recently, homologous recombination deficiency (HRD) has become a new target for hereditary cancers. Molecular-based approaches for hereditary cancers in the clinical setting have been reviewed. In particular, the efficacy of...
2.
Komatsu N, Chishima T, Watanabe C, Taruno K, Inuzuka M, Oshi M, et al.
Breast Cancer Res Treat
. 2024 Nov;
209(1):211-214.
PMID: 39520504
No abstract available.
3.
Tokunaga E, Iwata H, Itoh M, Taira T, Toyama T, Mizuno T, et al.
Breast Cancer
. 2024 Oct;
32(1):132-143.
PMID: 39379782
Background: In CAPItello-291, capivasertib-fulvestrant significantly improved progression-free survival (PFS) versus placebo-fulvestrant in the overall and PIK3CA/AKT1/PTEN-altered population with hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer....
4.
Komatsu N, Chishima T, Watanabe C, Taruno K, Inuzuka M, Oshi M, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(1):177-188.
PMID: 39356394
Purpose: With the increasing demand for BRCA genetic testing, most existing prediction models were developed using data from individuals of European descent. This study aimed to identify clinicopathological factors of...
5.
Daiki K, Kanada Y, Nagata A, Taruno K, Igarashi K, Yamochi T, et al.
Cancer Biomark
. 2024 Sep;
41(2):145-154.
PMID: 39331092
Background: Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood. Objective: This study aimed to investigate if the measurement of blood...
6.
Naito Y, Nakamura S, Kawaguchi-Sakita N, Ishida T, Nakayama T, Yamamoto Y, et al.
Int J Clin Oncol
. 2024 Sep;
29(11):1684-1695.
PMID: 39302614
Background: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate approved outside Japan for second-line and later metastatic triple-negative breast cancer (mTNBC), based on the ASCENT study (NCT02574455). We report SG...
7.
Ata-Shiroshita A, Kuwayama T, Kato M, Shinjo H, Miyaura K, Nagata A, et al.
Eur J Breast Health
. 2024 Sep;
20(3):215-222.
PMID: 39257014
Objective: Reports demonstrating the effectiveness and safety of strut-adjusted volume implants (SAVI) in Japan are limited. Therefore, this study aimed to compare the treatment outcomes of SAVI and whole-breast irradiation...
8.
Yoshida R, Kaneyasu T, Ueki A, Yamauchi H, Ohsumi S, Ohno S, et al.
Breast Cancer
. 2024 Jul;
31(6):1028-1036.
PMID: 39003386
Background: Tailored, preventive cancer care requires the identification of pathogenic germline variants (PGVs) among potentially at-risk blood relatives (BRs). Cascade testing is carried out for BRs of probands who are...
9.
Okuyama H, Takada F, Taira N, Nakamura S
Breast Cancer
. 2024 May;
31(5):787-797.
PMID: 38796818
Background: Electronic patient-reported outcomes (ePRO) monitoring is a useful communication tool for cancer patients and healthcare providers. In this study, we examined the impact of symptom monitoring using an ePRO...
10.
Verhoeven D, Siesling S, Allemani C, Roy P, Travado L, Bhoo-Pathy N, et al.
Oncologist
. 2024 May;
29(7):e899-e909.
PMID: 38780115
Breast cancer care is a costly global health issue where effective management depends on early detection and treatment. A breast cancer diagnosis can result in financial catastrophe especially in low-...